Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex

Current Pharmaceutical Design

Volumn 16, Issue 5, 2010, Pages 502-515

  López Gil, Xavier ^a,b   Artigas, Francesc ^a,b   Adell, Albert ^a,b  

^a INST D INVESTIGACIONS B   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

5 ht1a receptor; Dopamine d1 d2 d3 d4 receptors; Glutamate; MK 801; Prefrontal cortex; Serotonin

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 4 AMINOBUTYRIC ACID RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PRAZOSIN; RACLOPRIDE; REPINOTAN; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; UNINDEXED DRUG; VOLINANSERIN;

4 AMINOBUTYRIC ACID RELEASE; BRAIN NERVE CELL; CELL POPULATION; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG MECHANISM; GLUTAMATERGIC SYSTEM; HUMAN; INTERNEURON; MICRODIALYSIS; MONOAMINERGIC SYSTEM; NERVE CELL EXCITABILITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR BLOCKING; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

EID: 77949455392     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790361416     Document Type: Review

References (178)

1. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
3. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998; 12: 21-36.
4. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
5. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455-67.
6. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-7.
7. Hertel P, Mathé JM, Nomikos GG, Iurlo M, Mathé AA, Svensson TH. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 1995; 72: 103-14.
8. Adams BW, Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 2001; 50: 750-7.
9. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004; 29: 1259-69.
10. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993; 57: 1-78.
11. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-52.
12. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-25.
13. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-36.
14. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-7.
15. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117: 697-706.
16. Ceglia I, Carli M, Baviera M, Renoldi G, Calcagno E, Invernizzi RW. The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. J Neurochem 2004; 91: 189-99.
17. 1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J Neurochem 2006; 96: 853-8.
18. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK 801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007; 32: 2087-97.
19. Schmidt CJ, Fadayel GM. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 1996; 277: 1541-9.
20. Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 1998; 18: 5545-54.
21. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999; 11: 4419-32.
22. Amargós-Bosch M, López-Gil X, Artigas F, Adell A. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol 2006; 9: 565-73.
23. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003; 169: 215-33.
24. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-500.
25. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-43.
26. Li Q, Clark S, Lewis DV, Wilson WA. NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J Neurosci 2002; 22: 3070-80.
27. Hajós M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 2006; 27: 391-8.
28. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49: 943-58.
29. Siegel BV, Jr., Buchsbaum MS, Bunney WE, Jr., Gottschalk LA, Haier RJ, Lohr JB, et al. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 1993; 150: 1325-36.
30. Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, et al. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 1995; 52: 657-67.
31. Norman RM, Malla AK, Morrison-Stewart SL, Helmes E, Williamson PC, Thomas J, et al. Neuropsychological correlates of syndromes in schizophrenia. Br J Psychiatry 1997; 170: 134-9.
32. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-19.
33. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-20.
34. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9.
35. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatr Clin Neurosci 1996; 8: 223-6.
36. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90.
37. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-7.
38. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158: 360-9.
39. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004; 4: 53-7.
40. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-93.
41. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003; 9: 404-16.
42. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004; 174: 3-16.
43. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-6.
44. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
45. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
46. 1A receptors. J Pharmacol Exp Ther 2000; 295: 853-61.
47. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49: 861-8.
48. 1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 2007; 32: 78-94.
49. Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008; 55: 1056-65.
50. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193-7.
51. Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13: 204-9.
52. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101.
53. Svensson TH. α-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1145-58.
54. Alsene KM, Carasso BS, Connors EE, Bakshi VP. Disruption of prepulse inhibition after stimulation of central but not peripheral α-1 adrenergic receptors. Neuropsychopharmacology 2006; 31: 2150-61.
55. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156: 117-54.
56. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998; 136: 153-61.
57. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005; 25: 10831-43.
58. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998; 812: 65-75.
59. 1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem 2003; 87: 831-42.
60. Amargós-Bosch M, Adell A, Artigas F. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex. J Neurochem 2007; 102: 550-61.
61. 2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 2006; 31: 757-67.
62. López-Gil X, Artigas F, Adell A. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol 2009; 12: 487-99.
63. Abekawa T, Ito K, Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidineinduced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2006; 374: 177-93.
64. Homayoun H, Moghaddam B. Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry 2007; 61: 679-87.
65. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 2007; 104: 14843-8.
66. Fuster JM. The prefrontal cortex-an update: time is of the essence. Neuron 2001; 30: 319-33.
67. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000; 28: 325-34.
68. Celada P, Castañé A, Adell A, Artigas F. Modeling schizophrenia in experimental animals. In: Buschmann H, Díaz JL, Holenz J, Párraga A, Torrens A, Vela JM, Eds. Antidepressants, antipsychotics, anxiolytics. From chemistry and pharmacology to clinical application. Weinheim: Wiley-VCH 2007; pp. 449-89.
69. Hervás I, Queiroz CM, Adell A, Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol 2000; 130: 160-6.
70. West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002; 22: 294-304.
71. Martín-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 2001; 21: 9856-66.
72. Oerther S, Ahlenius S. Atypical antipsychotics and dopamine D1 receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 2000; 292: 731-6.
73. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for "atypicality"? Clin Neurosci Res 2003; 3: 108-17.
74. 2-adrenoceptor antagonism. Neuropsychopharmacology 1997; 17: 44-55.
75. Ichikawa J, Kuroki T, Dai J, Meltzer HY. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 1998; 351: 163-71.
76. Hertel P, Fagerquist MV, Svensson TH. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade. Science 1999; 286: 105-7.
77. Suzuki Y, Jodo E, Takeuchi S, Niwa S, Kayama Y. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 2002; 114: 769-79.
78. Jackson ME, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004; 101: 8467-72.
79. Katayama T, Jodo E, Suzuki Y, Hoshino KY, Takeuchi S, Kayama Y. Activation of medial prefrontal cortex neurons by phencyclidine is mediated via AMPA/kainate glutamate receptors in anesthetized rats. Neuroscience 2007; 150: 442-8.
80. Takahata R, Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003; 28: 1117-24.
81. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-13.
82. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995; 120: 365-8.
83. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612-27.
84. Gabbott PL, Warner TA, Jays PR, Salway P, Busby SJ. Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. J Comp Neurol 2005; 492: 145-177.
85. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53: 119-33.
86. Tang L, Todd RD, Heller A, O'Malley KL. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 1994; 268: 495-502.
87. Assié MB, Dominguez H, Consul-Denjean N, Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 441-50.
88. Mathé JM, Nomikos GG, Blakeman KH, Svensson TH. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 1999; 38: 121-8.
89. Wang Y, Goldman-Rakic PS. D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc Natl Acad Sci USA 2004; 101: 5093-5.
90. Vincent SL, Khan Y, Benes FM. Cellular colocalization of dopamine D1 and D2 receptors in rat medial prefrontal cortex. Synapse 1995; 19: 112-20.
91. Khan ZU, Gutiérrez A, Martin R, Peñafiel A, Rivera A, De La Calle A. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtyp-especific antibodies in rat and human brain. J Comp Neurol 1998; 402: 353-71.
92. 2 dopamine receptor subtypes. Brain Res Mol Brain Res 1998; 58: 231-6.
93. Santana N, Mengod G, Artigas F. Quantitative Analysis of the Expression of Dopamine D1 and D2 Receptors in Pyramidal and GABAergic Neurons of the Rat Prefrontal Cortex. Cereb Cortex 2009; 19: 849-60.
94. Benes FM, Taylor JB, Cunningham MC. Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology. Cereb Cortex 2000; 10: 1014-27.
95. Sesack SR, Hawrylak VA, Melchitzky DS, Lewis DA. Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures. Cereb Cortex 1998; 8: 614-22.
96. Gorelova N, Seamans JK, Yang CR. Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 2002; 88: 3150-66.
97. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25: 1-27.
98. De Felipe J. Cortical interneurons: from Cajal to 2001. Prog Brain Res 2002; 136: 215-38.
99. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001; 21: 3628-38.
100. Gao WJ, Wang Y, Goldman-Rakic PS. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J Neurosci 2003; 23: 1622-30.
101. Benes FM. Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain. Schizophr Bull 1998; 24: 219-30.
102. Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002; 52: 708-15.
103. Benes FM. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J Psychiatr Res 1997; 31: 257-75.
104. Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol 1997; 7: 701-7.
105. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C. Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 2004; 5: 793-807.
106. Hájos N, Pálhalmi J, Mann EO, Németh B, Paulsen O, Freund TF. Spike timing of distinct types of GABAergic interneuron during hippocampal gamma oscillations in vitro. J Neurosci 2004; 24: 9127-37.
107. Tukker JJ, Fuentealba P, Hartwich K, Somogyi P, Klausberger T. Cell type-specific tuning of hippocampal interneuron firing during gamma oscillations in vivo. J Neurosci 2007; 27: 8184-9.
108. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 2008; 34: 944-61.
109. Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 1996; 7: 1945-8.
110. Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 1996; 381: 245-8.
111. Defagot MC, Antonelli MC. Autoradiographic localization of the putative D4 dopamine receptor in rat brain. Neurochem Res 1997; 22: 401-7.
112. Defagot MC, Malchiodi EL, Villar MJ, Antonelli MC. Distribution of D4 dopamine receptor in rat brain with sequence-specific antibodies. Brain Res Mol Brain Res 1997; 45: 1-12.
113. Ariano MA, Wang J, Noblett KL, Larson ER, Sibley DR. Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 1997; 752: 26-34.
114. Wedzony K, Chocyk A, Mackowiak M, Fijal K, Czyrak A. Cortical localization of dopamine D4 receptors in the rat brain-immunocytochemical study. J Physiol Pharmacol 2000; 51: 205-21.
115. Noaín D, Avale ME, Wedemeyer C, Calvo D, Peper M, Rubinstein M. Identification of brain neurons expressing the dopamine D4 receptor gene using BAC transgenic mice. Eur J Neurosci 2006; 24: 2429-38.
116. Abi-Dargham A. Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? World Psychiatry 2003; 2: 166-71.
117. Bubenikova-Valesova V, Svoboda J, Horacek J, Vales K. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpinetreated rats. Int J Neuropsychopharmacol 2009; 12: 873-83.
118. Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic PS. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 1995; 15: 7821-36.
119. Davidoff SA, Benes FM. High-resolution scatchard analysis shows D1 receptor binding on pyramidal and nonpyramidal neurons. Synapse 1998; 28: 83-90.
120. Glausier JR, Khan ZU, Muly EC. Dopamine D1 and D5 receptors are localized to discrete populations of interneurons in primate prefrontal cortex. Cereb Cortex 2009; 19: 1820-34.
121. Muly EC, III, Szigeti K, Goldman-Rakic PS. D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization. J Neurosci 1998; 18: 10553-65.
122. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
123. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996; 277: 968-81.
124. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 2004; 14: 281-99.
125. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997; 27: 79-82.
126. 2A receptor in the central nervous system of adult rat. J Comp Neurol 1999; 409: 187-209.
127. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004; 14: 1100-9.
128. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991; 40: 399-412.
129. 2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 1994; 17: 173-81.
130. A, and glutamate receptors. J Neurosci 2001; 21: 9917-29.
131. De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, et al. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. J Pharmacol Exp Ther 1998; 284: 1082-94.
132. 1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res 2003; 989: 42-51.
133. 1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res 2003; 959: 58-67.
134. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, et al. Cloning and pharmacological characterization of human α-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther 1995; 272: 134-42.
135. 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 1999; 367: 197-206.
136. 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 1997; 13: 115-39.
137. 1A adrenergic receptor mRNA in the rat brain visualized by in situ hybridization. J Comp Neurol 1997; 386: 358-78.
138. 1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype-specific probes. J Neurosci 1994; 14: 4252-68.
139. 125I]- heat. J Comp Neurol 1985; 231: 190-208.
140. 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res 1987; 419: 65-75.
141. Kuroda M, Yokofujita J, Murakami K. An ultrastructural study of the neural circuit between the prefrontal cortex and the mediodorsal nucleus of the thalamus. Prog Neurobiol 1998; 54: 417-58.
142. Groenewegen HJ, Uylings HBM. The prefrontal cortex and the integration of sensory, limbic and autonomic function. Prog Brain Res 2000; 126: 3-28.
143. Heidbreder CA, Groenewegen HJ. The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehav Rev 2003; 27: 555-79.
144. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
145. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.
146. Ashby CR, Jr., Edwards E, Harkins K, Wang RY. Effects of (±)-DOI on medial prefrontal cortical cells: a microiontophoretic study. Brain Res 1989; 498: 393-6.
147. Tanaka E, North RA. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 1993; 69: 1749-57.
148. Aghajanian GK, Marek GJ. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997; 36: 589-99.
149. 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 1999; 11: 2917-34.
150. Zhou FM, Hablitz JJ. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol 1999; 82: 2989-99.
151. 3 receptors mediate serotonergic fast synaptic excitation of neocortical vasoactive intestinal peptide/cholecystokinin interneurons. J Neurosci 2002; 22: 7389-97.
152. 2A receptors: relationship to thalamocortical afferents. Cereb Cortex 2003; 13: 870-82.
153. Pehek EA, Yamamoto BK. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 1994; 63: 2118-24.
154. 1A receptor activation. Eur J Pharmacol 1997; 338: R3-R5.
155. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76: 1521-31.
156. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005; 315: 265-72.
157. Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007; 191: 745-58.
158. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000; 48: 229-37.
159. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288: 774-81.
160. 1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebocontrolled study. Schizophr Res 2007; 95: 158-68.
161. 1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm 2000; 107: 1229-38.
162. Freund TF, Katona I. Perisomatic inhibition. Neuron 2007; 56: 33-42.
163. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 2008; 34: 944-61.
164. Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 1999; 84: 193-6.
165. Millan MJ. N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 2005; 179: 30-53.
166. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1-93.
167. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
168. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109: 411-20.
169. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26: 649-66.
170. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000; 31: 302-12.
171. Marek GJ. Metabotropic glutamate 2/3 receptors as drug targets. Curr Opin Pharmacol 2004; 4: 18-22.
172. Galarreta M, Hestrin S. A network of fast-spiking cells in the neocortex connected by electrical synapses. Nature 1999; 402: 72-5.
173. Cruikshank SJ, Lewis TJ, Connors BW. Synaptic basis for intense thalamocortical activation of feedforward inhibitory cells in neocortex. Nat Neurosci 2007; 10: 462-8.
174. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-24.
175. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452: 93-7.
176. Lezoualc'h F, Jockers R, Berque-Bestel I. Multivalent-based drug design applied to serotonin 5-HT(4) receptor oligomers. Curr Pharm Des 2009; 15(6): 719-29.
177. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15(14): 1563-86.
178. Nishida A, Miyaoka T, Inagaki T, Horiguchi J. New approaches to antidepressant drug design: cytokine-regulated pathways. Curr Pharm Des 2009; 15(14): 1683-7.